October 2017 Essential Diabetes Drugs Revised February 13 ...
ESSENTIAL DRUGS in the Philippines
description
Transcript of ESSENTIAL DRUGS in the Philippines
ESSENTIAL DRUGS
in the
PhilippinesJoselito Quinitio, DDM
INTRODUCTION
• “Essential drugs are those that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in the appropriate dosage forms.” –The use of essential drugs, WHO, 1990
2
• “Access to essential medicines pertains to the equitable and sustainable availability and affordability of safe, efficacious and quality medicines in a health facility or medicines outlet, within one hour’s walk from the patient’s home that enable a health system to achieve better health outcomes for its people.” – World Medicines Situation, WHO, 2004
3
CURRENT SITUATION IN THE PHILIPPINES• In the Philippines, about 3.84% of the Gross Domestic Product (GDP)
is spent on health care where 54.3% of health expenditures are paid out of pocket (National Health Accounts, 2007)
• 65% of total out-of-pocket expenditures goes to medicines putting more burden on the poorest quintile of the population (FIES, 2009)
4
• 2nd largest component of govt. expenditures in terms of payments made through the National Health Insurance Program (NHIP) at about 1/3 of all reimbursement made by PhilHealth in 2010
• At least 30% of Filipinos lack regular and sustainable access to essential medicines
• In 2004, the World Medicines Situation Report identified the Philippines as one of 64 countries worldwide with low to medium regular access to essential medicines (WHO, 2004)
5
CURRENT SITUATION IN THE PHILIPPINES
• Medicine prices in the Philippines have been historically high compared to other countries
• In 2006, a drug price survey by WHO and the Health Action International revealed that Filipinos are among those who pay the highest drug prices in Asia with innovator brands costing 16x more and generic drugs costing 15x more when compared with international reference prices
6
CURRENT SITUATION IN THE PHILIPPINES
UNIVERSAL HEALTH CARE IN THE PHILIPPINES• Universal Health Care (UHC) is the call and commitment of the
Philippine government to ensure that every Filipino has access to quality and affordable health care
• In 2011, the Kalusugan Pangkalahatan (KP) was launched by the Aquino govt. to address the goal of the DOH to achieve UHC by 2016
7
• KP is defined as the “provision to every Filipino of the highest possible quality of health care that is accessible, efficient, equitability distributed, adequately funded, fairly financed, and appropriately used by an informed and empowered public.”
8
KP’S 3 STRATEGIC THRUSTS
1. Achieve the health-related Millennium Development Goals (MDGs) of improving maternal and child health and combating priority infectious and non-communicable diseases
2. Provide financial risk protection through expansion in the enrollment and benefit delivery of the National Health Insurance Program (NHIP)
9
KP’S 3 STRATEGIC THRUSTS
3. Improve access to quality health care which includes the upgrading of public hospitals and health facilities, ensuring adequate health human resources and securing the availability of essential drugs
10
PHILIPPINE MEDICINES POLICY
• In line with the govt. policy to deliver UHC by 2016, the PhilippineMedicines Policy (PMP) was adopted in 2011
• PMP 2011 – 2016 is a comprehensive plan to ensure access to essential medicines for all Filipino now and into the future
11
• The overall responsibility for the management, monitoring and evaluation of the PMP shall be the DOH-National Center for Pharmaceutical Access and Management (DOH-NCPAM)
12
PHILIPPINE MEDICINES POLICY
SARAH MEDICINES ACCESS FRAMEWORK• The SARAH Medicines Access Framework consists of the five
major pillars of the Philippine Medicines Policy
• The 5 pillars cover all the components that are necessary to ensure that essential and quality medicines are accessible and available to achieve better health outcomes for all Filipinos especially the poor
13
5 PILLARS OF SARAH
1. Safety, Efficacy and Quality (SEQ) of medicines2. Affordability and Availability3. Rational Drug Use4. Accountability, Transparency and Good Governance5. Health Systems Support
14
15
SARAH Access Framework
1. SAFETY, EFFICACY AND QUALITY (SEQ)• Includes all policies and strategies by the govt. to assure the safety,
efficacy and quality of essential medicines along the supply chain and at all levels of care
• Manufacture, packaging, procurement, import, export, distribution, supply and sale of drugs, product promotion and advertising and clinical trials – strict adherence to standards of safety, efficacy and quality
16
1. SAFETY, EFFICACY AND QUALITY (SEQ)• Food and Drug Administration (FDA) – lead agency that develops
and implements regulations concerning safety, efficacy and quality of drugs
• Formerly was called Bureau of Food and Drugs (BFAD)
• Enforces the laws and regulations concerning the drug regulatory system involving all parties in the drug supply chain
17
1. SAFETY, EFFICACY AND QUALITY (SEQ)• FDA programs to ensure safety of drugs:
a. National Pharmacovigilance Program – a system of reporting and surveillance of adverse drug reactions, drug alerts or any event which brings into question the safety, efficacy and quality of drugs (vaccines, medicines, contrast media, herbal products and food supplements)
18
1. SAFETY, EFFICACY AND QUALITY (SEQ)
b. Combating counterfeit medicines• Counterfeit medicines – medicinal products which are deliberately and
fraudulently mislabeled with respect to identity and/or source sold under a product name without proper authorization
• Coordination among govt. agencies such as Bureau of Customs. Philippine Post Office, NBI, PNP, etc. and private sector to combat counterfeit medicines
• FDA is also tasked with educating the public on the dangers of using counterfeit medicines
19
1. SAFETY, EFFICACY AND QUALITY (SEQ)• The FDA also enforces compliance of drug manufacturers and
distributors to Current Good Manufacturing Practices (cGMP), goodstorage and distribution practices (GDP, GSP)
• FDA also regularly conducts inspections of manufacturing plants and health care facilities in relation to medicines quality assurance
20
2. AVAILABILITY AND AFFORDABILITY• The goal is to ensure the continuous availability of essential medicines
in the health care system at prices that are within reach of patients, consumers and the govt.
• Govt. programs to improve availability and affordability 1. Medicines Access Program (MAPs)2. Consignment3. Pricing policies4. TRIPS Flexibilities5. Use of traditional and alternative medicines
21
2. AVAILABILITY AND AFFORDABILITY• Medicines Access Programs (MAPs) – since 2011, DOH has
pursued free medicines access programs to the poor as a strategy toward UHC
• Priority Areas:1. Outpatient drugs for common infections, hypertension and diabetes2. Inpatient drugs for some catastrophic diseases such as breast cancer,
childhood acute lymphocytic leukemia (ALL)
22
2. AVAILABILITY AND AFFORDABILITY• MAPs for out-patient care:
a. Botika ng Barangay (BnB) – a drug outlet with special license to operate from the FDA to improve access to essential medicines especially by the poor
Can be managed by community organization, NGO and/or LGU with a trained operator and visiting pharmacist
23
24
2. AVAILABILITY AND AFFORDABILITYVariants:
a. Botika Para sa Taumbayan – a partenership with the Civil Service Commission
b. Botika ng Manggagawa – a partnership with the Philippine Government Employees Association
c. Health Plus Outlet – a partnership with the National Pharmaceutical Foundation
d. Botika Binhi – a partnership with the Kabalikat ng Botika Binhi, Inc.
25
2. AVAILABILITY AND AFFORDABILITY• MAPs for outpatient care:
DOH COMPLETE TREATMENT PACKAGES (COMPACKS)Free drug access program for poor families covered by the Pantawid Pamilya
Pinoy Program (4Ps) introduced in 2011
25 complete treatment regimens for the most common diseases: infections, hypertension, DM, asthma
26
27
DOH COMPACK PROGRAM
• For out-patient care (to be interfaced with the PhilHealth Primary Care Benefit Packages)
• By 2013:To cover all RHUs nationwideTo include all PhilHealth sponsored members and indigenous people as
beneficiaries
28
Cancer Medicines Access Porgram1. Breast Cancer Medicines Access Program (BCMAP)1,356 patients enrolled in 6 DOH hospitals
2. Acute Lymphocytic Leukemia in Children (ALLMAP)867 patients enrolled in 14 DOH hospitals
29
• Other MAPs1. DOH Insulin Access Program2. Valsartan Access Program3. Geriatric Health Care Medicines Access Program4. Mental Health Care Medicines Access Program
30
2. AVAILABILITY AND AFFORDABILITY
• Medicine consignment system by the DOH allows government health facilities to deliver essential medicines to patients at no cost to the government
• The consignment system must comply with systems and guidelines set forth by the DOH and the Government Procurement Policy Board
31
2. AVAILABILITY AND AFFORDABILITY
• Pricing Policy for Medicines • To ensure that essential medicines are affordable, the government
shall undertake the following measures:a. Price Advisory Council – monitors drug prices and recommends policy options
for fair and rational pricing of medicines
b. Voluntary Drug Price Reduction – the govt. shall negotiate with the industry to voluntarily reduce prices particularly for medicines included in the Essential Drug List or the Philippine National Formulary
32
2. AVAILABILITY AND AFFORDABILITY
c. Medicines Price Board – created to set and negotiate for fair and transparent prices of all drugs in the national formulary
d. Electronic Essential Drug Price Monitoring System (e-EDPMS) and Drug Price Reference Index (DPRI)
EDPMS is a computer-based monitoring system for the collecting, submitting, processing and analyzing prices and inventories of drugs
33
2. AVAILABILITY AND AFFORDABILITY
34
2. AVAILABILITY AND AFFORDABILITY
EDPMS (http://uhmis4.doh.gov.ph/edpms)
• Drug Price Reference Index (DPRI) 1. Lists the ceiling prices of essential medicines for government bidding and
procurement set by the DOH for all DOH Retained Hospitals and Regional Offices
2. Aims to improve the efficiency and good governance in the pricing and procurement of medicines in the public sector through establishing a transparent and publicly available reference price for medicines
3. Helps guide PhilHealth in setting reimbursement caps for medicines both for inpatient and outpatient services
35
2. AVAILABILITY AND AFFORDABILITY
36
DPRI
Highly Inefficient Public Sector Procurement
37
e. Special discounts for medicines – for seniors and PWDs
f. Tax incentives such as lower taxes for pharmaceutical companies or exemption from taxes, tariffs or duties on life-saving medicines to lower cost for patients
38
2. AVAILABILITY AND AFFORDABILITY
g. Generics PolicyThe primary instrument recognized by the govt. to reduce prices of medicines
is effective competition and the active promotion, adoption and use of generics
Generic medicines – health products that have the same quality and efficacy as branded innovator drugs but give patients more choice because of their lower price
39
2. AVAILABILITY AND AFFORDABILITY
Generics law of 1988 (ra 6675)
• Promotes, encourages and require the use of generic terminology in the importation, manufacture, distribution, marketing, advertising and promotion, prescription and dispensing of drugs
• Ensures the adequate supply of drugs with generic names at the lowest possible cost and endeavor to make them available for free to indigent patients
• Encourages the extensive use of drugs with generic names through a rational system of procurement and distribution
40
• Gave the govt. instruments to ensure the affordability of drugs to patients and consumers
• Power to set maximum retail prices of drugs sold in the Philippines as a consumer protection pillar
• Power to invoke TRIPS flexibilities particularly for public health emergencies and other situations as deemed necessary by the Secretary of Health
41
Universally Accessible Cheaper & Quality Medicines Act of 2008 (RA 9502)
h. TRIPS Flexibilities - Trade Related Aspects of Intellectual Property Rights
• TRIPS is a comprehensive global (WTO) agreement in the field of intellectual property and covers a wide range of subjects; patents for pharmaceutical products are only part of the agreement
• The TRIPS agreement provides flexibility for governments to change the protection for patented products in order to meet social goals (e.g. health crises, national emergencies)
42
2. AVAILABILITY AND AFFORDABILITY
1. Parallel importation of patented drugs• Parallel imports are imports of a patented or trademarked product
from a country where it is already marketed.
Mozambique – 100 units of ciprofloxacin (Bayer) costs US$740 India – 100 units of ciprofloxacin (Bayer) costs US$15
Mozambique can import the product from India without Bayer’s consent
43
Trips flexibilities
2. Compulsory licensing• A govt. allows someone else to produce a patented drug without the
consent of the patent owner
44
Trips flexibilities
i. Use of Traditional and Alternative Medicines• Traditional and alternative medicines approved by the DOH give patients
wider choices to low cost and effective treatment while providing a local source of livelihood and income to local manufacturers
45
2. AVAILABILITY AND AFFORDABILITY
3. RATIONAL USE OF MEDICINES (RUM)• RUM is the condition where patients receive medicines appropriate for
their clinical needs, in doses that meet their individual requirements, for an adequate period of time and at the lowest possible cost to them and their communities – WHO
• The goal of RUM is to promote quality use of drugs in the public and private sectors using cost-effective and rational treatments that will result in the best health outcomes for patients
46
• Basic tenets of RUM:1. Prescribing medicines only when these are necessary2. Prescribing medicines appropriately (correct dosage and proper length of
time)3. Considering the benefits of administering medicines in relation to the risks
involved (risk benefit)
47
3. RATIONAL USE OF MEDICINES (RUM)
• The key strategy under RUM is the development and implementation of a Philippine National Drug Formulary (PNDF) (Essential Drug List of the Philippines)
• The PNDF is a list of essential medicines deemed important to address the primary health care needs of Filipinos
• It is the basis of all government procurement of medicines and reimbursement of drugs of PhilHealth
48
3. RATIONAL USE OF MEDICINES (RUM)
49
3. RATIONAL USE OF MEDICINES (RUM)
50
3. RATIONAL USE OF MEDICINES (RUM)
• Movement to combat AMR (anti-microbial resistance) by raising awareness on the growing threats of AMR, promoting the responsible use of antibiotics and preventing the spread of infections
• AMR is simply the ability of microbes, to grow in the presence of a chemical, or a drug, that would normally kill it or inhibit its growth
51
3. RATIONAL USE OF MEDICINES (RUM)
• The DOH established the Antimicrobial Resistance Surveillance Program(ARSP) in 1988 to determine the current status and developing trends of AMR
52
3. RATIONAL USE OF MEDICINES (RUM)
53
3. RATIONAL USE OF MEDICINES (RUM)
54
3. RATIONAL USE OF MEDICINES (RUM)
4. ACCOUNTABILITY, TRANSPARENCY AND GOOD GOVERNANCE• The goal is to institutionalize transparency, accountability and good
governance along the registration, regulation, selection, procurement and management of medicines in the health sector
• These measures shall be pursued through the following mechanisms:a. Access to information – there shall be transparent data and information
sharing among all the agencies, manufacturers, retailers, service providers and consumer groups with regard to medicine prices, drug registration status, status of regulatory compliance and other critical transactions, decisions and processes with regard to medicines
55
b. Managing conflicts of interests – the DOH shall provide a clear criteria in the selection and appointment of members to decision making committees (Formulary Executive Council, Bids and Awards Committees, Drug Therapeutic Committees)
c. Efficient, transparent and accountable processes
d. Standards of good governance – a rewards and incentives system shall be developed and implemented for Good Governance in Medicines
56
4. ACCOUNTABILITY, TRANSPARENCY AND GOOD GOVERNANCE
5. HEALTH SYSTEMS SUPPORT
• The goal is to ensure that there is adequate health systems support from the govt. and all stakeholders to ensure the effective implementation of the PMP in the following areas:
a. Human resourcesb. Local research and developmentc. Medicines information systemd. Local govt. supporte. Public private partnerships
57
58
Thank You for Listening.